Atlas Trials

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

Clinical trial NCT06027268 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06027268
Sponsor
Wake Forest University Health Sciences
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Triple-Negative Breast Cancer
Start date
2024-01-10
Primary completion
2027-08-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.